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Abstract
OBJECTIVE: To provide clinical evidence in support
of Dahuang Huanglian Xiexin decoction (DHXD) to
treat type 2 diabetes mellitus (T2DM) and to intro-
duce a new treatment option for clinicians.
METHODS: Retrospective analysis was used to eval-
uate DHXD for the treatment of T2DM by analyzing
clinical records of 183 cases. Patients with T2DM
who met the inclusion criteria between January 1,
2013 and January 1, 2014 were enrolled. The effects
of the treatment were evaluated by the changes in
fasting blood-glucose (FBG), postprandial blood
sugar (PBG), hemoglobin A1c (HbAlc), blood lipid
profiles and body mass index (BMI) at 1, 2, 3 and 6
months. The changes in main symptoms were also
evaluated. The dosage of Huanglian (Rhizoma Copti-
dis) and related factors were analyzed.
RESULTS: There was a significant improvement in
mean HbA1C at 3 and 6 months after DHXD treat-
ment compared with the baseline level (P < 0.01).
There were also significant improvements in FBG,
PBG, blood lipid series and BMI. DHXD also im-
proved the main symptoms of stomach and intes-
tine excessive heat syndrome in patients with
obese T2DM. Huanglian (Rhizoma Coptidis) was the
most frequently used in 678 clinical visits, the dos-
age of Huanglian (Rhizoma Coptidis) was related to
age, BMI, DM duration, the level of blood glucose,
and use ofWestern hypoglycemic drugs.
CONCLUSION: This study suggests that DHXD
could decrease blood glucose and improve T2DM
symptoms and reduce body weight. The use of
DHXD may indicate a new optional treatment for
T2DM.
© 2016 JTCM. All rights reserved.
Key words: Diabetes mellitus, type 2; Blood glu-
cose; Body weight; Dahuang Huanglian Xiexin de-
coction; Retrospective studies
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is the predominant
form of DM, which accounts for 95% of the global dia-
betes population.1,2 The cause of T2DM has not yet
been fully elucidated, although both genetic and envi-
ronmental factors (obesity and sedentary lifestyles) are
commonly cited.3 China has the world's largest diabe-
tes population, with more than 92.4 million people af-
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fected.4 The standard therapy for DM includes diet, ex-
ercise, use of oral hypoglycemic drugs, and/or subcuta-
neous insulin injections.5 Traditional Chinese Medicine
(TCM) has been used to treat T2DM in China for
over 2000 years.6 Treatment by TCM has the advan-
tage of lower toxicity and/or fewer side effects, and
herbal medicine could provide multiple therapeutic ef-
fects on multiple targets.6-8 Professor Tong Xiaolin, an
expert in TCM for treating T2DM in China, reported
in a syndrome analysis study involving 2518 cases of
obese T2DM that stomach and intestine excessive heat
syndrome is common in obese T2DM.9 Prof. Tong10,11
suggested a method using Dahuang Huanglian Xiexin
Decoction (DHXD) to clear away the heat and direct
the turbidity downward. DHXD has been established
as a fundamental formula for stomach and intestine ex-
cessive heat syndrome in obese T2DM.12 By using large
scale randomized controlled trials (RCTs),13 our group
has confirmed that Chinese herbal medicine possesses
independent anti-hyperglycemic effects. In one study
with 122 cases of obese patients with T2DM, Kaiyu
Qingre Jiangzhuo formula (KQJF) (modified DHXD)
was given to the treatment group and metformin to
the control group. The results showed no statistically
significant difference between the two groups on lower-
ing the blood glucose (P > 0.05), and no obvious ad-
verse events were reported in the treatment group. This
was the first evidence of a Chinese herbal medicine
lowering blood glucose in clinical conditions.14 In the
present study, a retrospective analysis was used to evalu-
ate DHXD for the treatment of T2DM and for intro-
ducing a new treatment option for clinicians.
METHODS
General information
The clinical records from Professor Tong Xiaolin were
used as the database. Patients who met the inclusion
criteria between January 1, 2013 and January 1, 2014
were enrolled in the study. Progress of the study is
shown in Figure 1.
The diagnostic criteria were: (a) diagnosis of T2DM re-
ferred to World Health Organization (WHO) T2DM
diagnostic criteria (1999);15 and (b) TCM syndrome
differentiation referred to Guideline for TCM Diabetes
Prevention and Treatment (2007).16 The inclusion crite-
ria included: (a) minimum age of 18 years; (b) a con-
firmed diagnosis of T2DM; and (c) DHXD as the pri-
mary prescription. The baseline data were recorded as
follow-up data within 6 months of blood glucose or he-
moglobin A1c (HbAlC). Patients were excluded if they
had type 1 diabetesmellitus or had diabetic ketoacidosis.
Information collection and standardization
A full medical history was recorded, including general
information about diabetes, related diabetic complica-
tions, diagnosis, therapeutic treatments and prescribed
Establish the inclusion criteria and choose the cases
183 cases of type 2 diabetes collection (678 visits at
1-,2-,3-, or 6 months) through return visits
Information standardization, medical records,
databases establishment and information entry
All cases (n = 183)
Used herbal medicine
Alone (n = 69)
Western hypoglycemic drugs
combination (n = 114)
Reduced dosage (n = 30) Insulin (n = 49)
Original dosage (n = 80) Metformin (n = 52)
Increased dosage (n = 4) Others (n = 13)
Subgroup Analysis (n = 183)
FBG, PBG, HbA1C,
Blood lipids and BMI
Efficacy of main
symptoms
TCM treatment
on T2DM
Related factors of drug
use and its dosages
Figure 1 Progress of patients' information collected in the study
FBG: fasting blood-glucose; PBG: postprandial blood sugar; HbA1C: Hemoglobin A1c; BMI: Body mass index; TCM: Traditional Chi-
nese Medicine; T2DM: type 2 diabetes mellitus.
308
JTCM |www. journaltcm. com June 15, 2016 |Volume 36 | Issue 3 |
Pang B et al. / Clinical Study
medication, whether hypoglycemic drugs were used,
and whether the patient was suffering from any other
disease. All the information was inputted into Visual
FoxPro" software (vers 6.0, Microsoft Corporation,
Redmond, Washington D.C., USA), and cases which
metthe inclusion criteria were transferred to an Excel
table and screened out. EpiData 3.1 software (vers 3.1,
EpiData Association, Odense, Denmark) was used to
document the detailed medical histories.
Because of variations in the way the medical histories
were expressed, they were scrutinized for errors and,
where necessary, the language was standardized. The
criteria used for standardizing word choice were based
on the normative textbooks.17-20 For example, "sleep dis-
order", "sleeplessness", and "insomnia" were unified as
"insomnia"; "Da Huang", "Jiu Da Huang", "Jiu Jun"
were unified as "Da Huang"; "gliclazide" and "Da Mei
Kang" were unified as "gliclazide".
TCM therapy method
Stomach and intestine excessive heat syndrome was
identified in patients according to symptoms of dry
mouth, bad breath, dry stool, red or yellow tongue
coating, and rapid pulse. The therapeutic method used
was "clear away the heat and direct the turbidity down-
ward".21,22 DHXD was established as the primary pre-
scription, which was composed of Dahuang (Radix Et
Rhizoma Rhei Palmati) and Huanglian (Rhizoma Copti-
dis). Tianma (Rhizoma Gastrodiae) and Gouteng (Ram-
ulus Uncariae Rhynchophyllae cum Uncis) were added
for hypertension, Weilingxian (Radix et Rhizoma Clem-
atidis Chinensis) was added for hyperuricemia, and
Yinchen (Herba Artemisia Capillaris) andWuweizi (Fruc-
tus Schisandrae Chinensis) were added for fatty liver.
Patients took decoction twice daily, and evaluations
were performed at 1, 2, 3 and 6 months return visits.
HbAlC, BMI, FBG, PBG, cholesterol (CHO), triglyc-
eride (TG), high-density lipoprotein (HDL-C) and
low density lipoprotein (LDL-C) changes were mea-
sured before and after the treatment.
Statistical analysis
Statistical analyses were performed with SPSS software
(vers 17.0, SPSS Institute, Chicago, IL, USA). Frequen-
cies of main symptoms were summarized by numbers
(n) or percentages (% ). Quantitative indicators were
presented as the mean ± SD, P < 0.05 or P < 0.01 was
considered to be statistically significant, and compari-
sons of before and after treatment were tested using the
t-test or non-parametric test. Subjective symptoms
were recorded and baseline symptoms scored "2". After
the treatment, alleviated symptoms scored "1", disap-
peared symptoms scored "0", no symptom improve-
ment or worse symptoms scored "3". If no obvious
symptom appeared when first seeing a doctor, "0" was
scored. If symptoms began to appear after treatment, "
2" was scored. If symptoms were aggravated, then "3"
was scored.23
Subjects
Study subjects were outpatients at Guang'anmen Hos-
pital. All patients gave informed consent and the study
was approved by the Ethics Committee of Guang'an-
men Hospital of China Academy of Chinese Medical
Sciences.
RESULTS
Study population
A total of 183 patients with 678 clinical visits were in-
cluded. The treatment group was composed of 122
men (66.7%) and 61 women (33.4%) with a mean age
of (48 ± 13) years (range 18-79 years). The level of
HbA1c less than 7 appeared 24.29% (43/177), 7 to 8
appeared 30.50% (54/177), 8 to 9 appeared 20.34%
(36/177), the level of HbA1c more than 9 appeared
24.86% (44/177). Of 183 patients, 49 patients com-
bined with insulin, 52 patients combined with Metfor-
min, 32 combined with Acarbose, 15 combined with
Repaglinide, 10 combined with Glimepiride, 10 com-
bined with Gliclazide, 8 combined with Rosiglitazone.
Change in HbA1c
Patients may have different follow-up times according
to the severity of their symptoms and indicators in this
retrospective study. The number of patients at 0, 1, 2,
3 and 6 months were 177, 78, 56, 177 and 126, respec-
tively. Mean HbA1C at 0, 1, 2, 3 and 6 months was
8.0% ± 1.7%, 7.8% ± 1.5%, 7.7% ± 1.0%, 7.1% ±
1.1% and 6.8% ± 1.1%, respectively. There were signif-
icant differences between 0 and 3 months (P < 0.01)
and between 0 and 6 months (P < 0.01), but only de-
creasing trends between 0 and 1 month and between 0
and 2 months (P > 0.05), indicating that DHXD had
a beneficial effect on improving HbA1c and that a
time-effect relationship existed.
Results were also analyzed from the perspective of dif-
ferent uses of Western hypoglycemic drugs, and BMI
or DM duration. The results showed that HbA1C had
a decreasing trend at all follow-up points and showed
significant differences at 6 months compared with 0
months (P < 0.01 or P < 0.05), and the curative effect
increased as time progressed (Tables 1-3).
Change in blood glucose levels
The number of patients at 0, 1, 2, 3 and 6 months
were 167, 70, 53, 148 and 107 patients, respectively.
Mean FBG at 0, 1, 2, 3 and 6 months was (9.2 ± 2.6),
(8.6 ± 2.0), (8.7 ± 1.9), (8.2 ± 2.2) and (7.8 ± 1.8)
mmol/L, respectively. There were significant differenc-
es between 0 and 3 months (P < 0.01) and between 0
and 6 months (P < 0.01), but only decreasing trends
between 0 and 1 month (P > 0.05) and 0 and 2 months
(P > 0.05), indicating that DHXD is beneficial in con-
trolling FBG. The FBG decreased with patients who
used DHXD alone and also with those who used
DHXD plus the original dosage of hypoglycemic
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drugs. Before and after treatments were analyzed at 3
and 6 months and showed remarkable differences (P <
0.01 or P < 0.05). The FBG of patients who reduced
the dosage of hypoglycemic drugs during the treatment
had a decreasing trend, but did not show any signifi-
cant difference (P > 0.05) (Table 4). The number of pa-
tients at 0, 1, 2, 3 and 6 months with PBG results were
91, 42, 22, 68 and 39, respectively. The mean PBG at
0, 1, 2, 3 and 6 months was (14.3 ± 4.6), (13.7 ± 5.0),
(14.5 ± 4.4), (11.7 ± 3.7) and (11.4 ± 3.4) mmol/L, re-
spectively. There were significant differences between 0
and 3 months and between 0 and 6 months (P <
0.01), but only decreasing trends between 0 and 1
month and between 0 and 2 months (P > 0.05), indi-
cating that DHXD has a beneficial effect on control-
ling PBG, and as time progressed, the effect increased.
Change in body mass index (BMI)
The mean BMI of obese patients (BMI > 28 kg/m2)
during the study period were (30.2 ± 2.5), (29.6 ± 2.4)
and (28.9 ± 1.7) kg/m2 at 0, 3 and 6 months, respec-
tively. There was a significant difference in BMI be-
tween 0 and 6 months (P < 0.05), but not between 0
and 3 months (P > 0.05). In overweight patients (BMI
24-28 kg/m2), mean BMIs were (26.2 ± 1.3), (25.8 ±
1.3) and (25.4 ± 1.3) kg/m2 at 0, 3 and 6 months, re-
spectively. There were significant differences in BMI be-
tween 0 and 3 months (P < 0.05) and between 0
and 6 months (P < 0.01).
Change in blood lipid profiles
Seventy-four patients with CHO ＞ 5.17 mmol/L)
were analyzed, and the means were (6.03 ± 0.75),
(5.54 ± 0.94) and (5.55 ± 1.12) mmol/L at 0, 3 and 6
months, respectively. There were significant differences
between 0 and 3 months and between 0 and 6 months
(P < 0.01). Seventy-nine patients with TG (> 1.70
mmol/L) were analyzed, and the means were (3.2 ±
1.7), (2.6 ± 1.3) and (2.6 ± 1.5) mmol/L at 0, 3 and 6
months, respectively. There were significant differences
between 0 and 3 months and 0 and 6 months (P <
0.05). Fifty-nine patients with LDL-C (> 3.10 mmol/
L) were analyzed, and the means were (3.85 ± 0.76),
(3.49 ± 0.97) and (3.42 ± 1.02) mmol/L at 0, 3 and
6 months, respectively. There were significant differenc-
es between 0 and 3 and between 0 and 6 months (P <
Table 1 HbA1c comparison from the use of western drugs (%, xˉ ± s)
Use of western drugs
No use (n=69)
Reduce dosage (n=30)
Original dosage (n=80)
HbA1c 0 month
7.7±1.4 (n=67)
7.7±1.9 (n=34)
8.3±1.8 (n=73)
HbA1c 3 month
6.9±0.9a (n=67)
6.9±1.1 (n=34)
7.3±1.3b (n=73)
P value
0.031
0.09
0.000
HbA1c 6 month
6.6±0.8b (n=44)
6.5±0.8b (n=28)
7.1±1.3b(n=52)
P value
0.000
0.000
0.000
Notes: aP < 0.051; bP < 0.01, compared with 0 month. HbA1C: hemoglobin A1c.
Table 2 HbA1c comparison from the level of BMI (%, xˉ ± s)
BMI (kg/m2)
18-24 (n=50)
24-28 (n=84)
≥ 28 (n=47)
HbA1c 0 month
7.6±1.7 (n=48)
8.0±1.7 (n=82)
8.5±1.6 (n= 47)
HbA1c 3 month
7.0±1.2b (n=48)
7.0±1.0b (n=81)
7.5±1.2b (n=47)
P value
0.038
0.000
0.001
HbA1c 6 month
6.7±0.9a (n=35)
6.8±1.1a (n=61)
7.1±1.3a (n=29)
P value
0.006
0.000
0.000
Notes: aP < 0.01; bP < 0.05,compared with 0 month. HbA1C: hemoglobin A1c; BMI: Body mass index.
Table 3 HbA1c comparison from the duration of diabetes (%, xˉ ± s)
DM duration (years)
0-1 (n=44)
1-2 (n=16)
2-5 (n=44)
5-10 (n=36)
≥10 (n=43)
HbA1c 0 month
7.7±1.9 (n=43)
7.9±1.5 (n=15)
7.9±1.2 (n=45)
7.9±2.0 (n=35)
8.4±1.8 (n=41)
HbA1c 3 month
6.7±1.4 (n=43)a
7.0±1.5 (n=15)
7.2±1.0 (n=44)a
7.2±0.9 (n=36)
7.5±1.3 (n=40)b
P value
0.001
0.091
0.005
0.064
0.011
HbA1c 6 month
6.4±0.9 (n=30)a
6.2±0.6 (n=10)a
7.2±0.9 (n=30)a
7.0±1.2 (n=29)b
7.1±1.3 (n=27)a
P value
0.000
0.002
0.006
0.034
0.002
Notes: aP < 0.01; bP < 0.05,compared with 0 month. HbA1C: Hemoglobin A1c; DM: diabetes mellitus.
Table 4 Comparison between FBG and different dosages of combined hypoglycemic drugs (mmol/L, xˉ ± s)
Use of western drugs
No use (n=69)
Reduce dosage (n=30)
Original dosage (n=80)
FBG 0 month
8.9±2.0 (n=63)
8.2±2.2 (n=32)
9.7±3.0 (n=68)
FBG 3month
7.8±1.4 (n=60)a
7.5±1.4 (n=27)
8.6±2.7 (n=57)b
P value
0.000
0.144
0.026
FBG 6month
7.6±1.3 (n=38)a
7.3±1.4 (n=26)
8.1±2.1 (n=41)a
P value
0.000
0.051
0.004
Notes: compared with 0 month, aP < 0.01, bP < 0.05. FBG: fasting blood-glucose.
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0.05), which indicated that DHXD had beneficial ef-
fects on decreasing CHO, TG and LDL-C. Forty-two
patients with HDL-C (< 1.10 mmol/L) were analyzed,
and the means were (0.91 ± 0.12), (0.98 ± 0.22) and
(1.02 ± 0.24) mmol/L at 0, 3 and 6 months, respective-
ly. There was a significant difference between 0 and 6
months (P < 0.05), but only a decreasing trend be-
tween 0 and 3 months (P > 0.05).
Change in main symptoms
The frequencies of main symptoms showed that the
highest frequency was 163 cases for greasy tongue coat-
ing, followed by 152 for yellow tongue coating and
132 for red tongue. The subjective symptoms with
high frequency were dry mouth and thirst, fatigue, in-
somnia, loose and smelly stool, irritability and hyperhi-
drosis. Of 183 cases, 89.07% of patients suffered
greasy tongue coating, 83.06% yellow tongue coating,
72.13% red tongue, and 42.08% dry mouth and
thirst. With regards to the effectiveness of the treatment
for relieving the main symptoms, dry stool was obviously
alleviated with remission rates at 3 and 6 months of
95.08% and 90.16% , respectively. Remission rates of
dry mouth and thirst were 85.71% and 61.04% at 3
and 6 months, respectively. Remission rates of fatigue
were 61.43% and 80% at 3 and 6 months, respectively
(Table 5).
The use of Huanglian (Rhizoma Coptidis) and
related factors
Huanglian (Rhizoma Coptidis) was the most frequently
used herb in 678 clinical visits, the frequency reached
87.02%. We investigated factors affecting the dosage of
Huanglian (Rhizoma Coptidis) from five levels: ≥ 30 g,
15-29 g, 9-14 g, 6-8 g and < 6 g. From the perspective
of age, we can see the oldest people (mean age) were us-
ing 9 to 14g,and the youngest people (mean age) were
using more than 30 g. From the perspective of BMI,
the decrease of BMI caused consequent dosage reduc-
tion of Huanglian (Rhizoma Coptidis)Huanglian (Rhi-
zoma Coptidis), and the highest BMI patients were us-
ing more than 30g dosage of Huanglian (Rhizoma Cop-
tidis) Huanglian (Rhizoma Coptidis). The patients with
longest DM duration (mean) used 9 to 14 g, and pa-
tients with the shortest DM duration (mean) used 6 to
8g, suggesting that DM duration was short and the
blood glucose was easy to control, so the amount of
the Huanglian (Rhizoma Coptidis) was relatively less.
With the increase of blood glucose (HbA1c,FBG and
PBG), the amount of Huanglian (Rhizoma Coptidis)
was consequently increasing, the highest level of blood
glucose were using more than 30 g dosage of Huangli-
an (Rhizoma Coptidis). Moreover, the different dosages
of Huanglian (Rhizoma Coptidis) when using different
use of western drugs were analyzed. The means dosages
were (17 ± 9), (19 ± 10) and (20 ± 11) g when no use
of western drugs, reduced dosage of western drugs, and
increased dosage of western drugs, respectively, suggest-
ing that doctors could increase the dosage of Huangli-
an (Rhizoma Coptidis) under the condition that re-
duced dosage of western drugs, and when the patient
did not use Western hypoglycemic drugs, the dosage of
Huanglian (Rhizoma Coptidis) could be decreased (Ta-
ble 6).
DISCUSSION
TCM therapy of type 2 diabetes
The epidemic growth rate of obesity and an increasing
elderly population contribute to the prevalence of DM.
TCM has a long history of being used to treat DM in
China.6 Clinical practice has shown a bright future for
Table 5 Efficacy of treatment of main symptoms [n (%)]
Main symptoms
Greasy tongue coating
Yellow tongue coating
Red tongue
Dry mouth and thirsty
Fatigue
Dry stool
Insomnia
Loose and smelly stool
Irritability
Hyperhidrosis
Diarrhea
Eating can be satisfied
Bad breath
Abdominal distension
Frequency (n=183)
163 (89.07)
152 (83.06)
132 (72.13)
77 (42.08)
70(38.25)
61 (33.33)
49 (26.78)
46 (26.14)
40 (21.86)
34 (18.58)
17 (9.29)
16 (8.74)
15 (8.20)
6 (3.28)
3 month efficacy (n=183)
66 (40.49)
74 (48.68)
42 (31.82)
66 (85.71)
43 (61.43)
58 (95.08)
28 (57.14)
36 (78.026)
30 (75.00)
21 (61.76)
15 (88.24)
15 (93.75)
2 (13.33)
6 (100.00)
6 month efficacy (n=183)
79 (48.47)
103 (67.76)
35 (26.52)
47 (61.04)
56 (80.00)
55 (90.16)
31 (63.27)
39 (84.78)
32 (80.00)
25 (73.53)
17 (100.00)
15 (93.75)
6 (40.00)
6 (100.00)
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TCM in treating DM and its complications.24 Tong25
has proposed the concept of a "combination of symp-
tom, syndrome and disease" as a therapeutic guideline
for T2DM and other diseases. Syndrome differentia-
tion, which focuses on the clinical characteristics of in-
dividual patients, is necessary. Obese patients with dia-
betes are generally identified by stomach and intestine
excessive heat syndrome as indicated by the symptoms
of dry mouth, bad breath, dry stool, red or yellow
tongue coating, and thread slippery pulse. The thera-
peutic method aims to clear away the heat and direct
the turbidity downward,13,21,22 and DHXD has been es-
tablished as a common medication.
On the basis of TCM syndrome differentiation, Tong
has used some herbs aimed at the main symptoms of
patients, e.g., patients with abdominal distension are
generally given a combined Zhizhu Decoction consist-
ing of Zhishi (Fructus Aurantii Immaturus) and Baizhu
(Rhizoma Atractylodis Macrocephalae). Patients with dry
mouth and thirst are generally prescribed a combina-
tion of Gualou Muli Powder consisting of Tianhuafen
(Radix Trichosanthis) and Muli (Concha Ostreae). Final-
ly, as important evidence to evaluate the therapeutic ef-
ficacy of DHXD, the characteristics of T2DM and re-
lated chemical indicators must also be considered, e.g.,
patients with hypertension are given DHXD combined
with Tianma (Rhizoma Gastrodiae) and Gouteng (Ram-
ulus Uncariae Rhynchophyllae cum Uncis).
Dahuang Huanglian Xiexin Decoction originating
from the Treatise on Febrile Diseases written by Zhang
Zhongjing is used to treat excessive heat in the epigas-
trium blocking Qi movement. This classic prescription
consists of Huanglian (Rhizoma Coptidis) and Da-
huang (Radix et Rhizoma Rhei Palmati). Modern phar-
macological research has confirmed that Huanglian
possesses anti-hyperglycemic activity.26 Some studies
have also demonstrated that alcohol extracted from Da-
huang could decrease weight, regulate metabolic disor-
der, and improve insulin resistance.27 Dahuang and
Huanglian are a pair of drugs for clearing away the ex-
cessive heat from the stomach and intestine, and direct-
ing the turbidity downward. Thus, they are established
as a fundamental formula for stomach and intestine ex-
cessive heat syndrome in obese T2DM.12,13
Analysis of results
The study aim was to provide clinical evidence to sup-
port DHXD for treating T2DM. All participating pa-
tients were diagnosed with T2DM, and there were
more men than women(122 vs 61). Most patients(>
70%)weremiddle-agedwith aBMIhigher than24kg/m2,
an HbA1C that ranged from 7% to 9%, and DM dura-
tion of less than 10 years. These data reflect the clinical
characteristics of our study population. Patients with
T2DM in the early stages began developing excessive
heat where there was a history of over-eating and a sed-
entary life-style, which generally combined with the
clinical appearance of obesity and fatty liver, hyperlipid-
emia, hypertension and hyperuricemia.
To analyze the factors related to the effects of herbal
medicine, we conducted subgroup analysis. From the
perspective of mean HbA1c, HbA1c levels of obese pa-
tients were higher than that of overweight and nor-
mal-weight patients, which may be related to greater
body weight. Patients with reduced sensibility to the ef-
fects of herbal medicine and who had difficulties con-
trolling their blood glucose levels had increased
HbA1C. We also analyzed the relationship between
DM duration and HbA1C, indicating an increased
trend that DHXD treatment could be more effective
in the early stages of T2DM (< 10 years). We also ana-
lyzed the FBG levels of patients taking Western hypo-
glycemic drugs who had reduced the dosage during
treatment and found a decreased trend in FBG levels,
though this was not statistically significant (P > 0.05).
This result indicates that herbal and Western medi-
cines have a synergistic effect in decreasing FBG, but
again it was not statistically significant— probably ow-
ing to the large dosage reductions of the Western drugs
and the fewer number of cases. With regards to BMI,
the results showed a decreased trend in BMI levels with
treatment, indicating that DHXD has effects on reduc-
ing body weight. In addition, the results also showed
that DHXD helped correct lipid metabolism disorders
by decreasing levels of CHO, TG and LDL-C, and in-
creasing levels of HDL-C.
Furthermore, the results demonstrated that DHXD ef-
fectively improved the symptoms of fatigue, dry
month, thirst and dry stool. However, red tongue and
yellow tongue coating were only slightly improved. But
Table 6 The dosage of Huanglian (Rhizoma Coptidis) (g) and related factors ( xˉ ± s)
Related factor
Age (years)
BMI(kg/m2)
DM duration (years)
FBG (mmol/L)
HbA1c (%)
PBG (mmol/L)
≥30 g
46.4±10.8
26.5±3.2
4.7±4.0
9.0±2.6
7.9±1.5
13.8±4.8
15-29 g
47.9±12.8
25.6±3.2
5.4±5.7
8.8±2.4
7.6±1.4
13.3±4.3
9-14 g
53.2±15.0
25.6±3.7
7.0±9.2
7.5±1.7
6.5±1.1
10.4±3.8
6-8 g
46.4±13.4
24.1±2.6
3.6±4.9
7.4±1.2
6.0±0.8
11.4±2.8
<6 g
50.9±11.0
23.3±3.2
6.6±5.2
6.4±1.0
6.0±0.6
10.5±3.0
Notes: BMI: body mass index; DM: diabetes mellitus; FBG: fasting blood-glucose; HbA1C: hemoglobin A1c; PBG: postprandial blood
sugar.
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because they may be general symptoms caused by the
generation of heat syndrome, they could not improve
in the short term. Huanglian (Rhizoma Coptidis) was
the most frequently used herb in 678 clinical visits, the
dosage of Huanglian (Rhizoma Coptidis) was related to
age, BMI, DM duration, the level of blood glucose,
and use of western hypoglycemic drugs. With the in-
crease of BMI, DM duration and the level of blood glu-
cose, the dosage of Huanglian (Rhizoma Coptidis) was
generally increased, but the increase of age caused con-
sequent dosage reduction of Huanglian (Rhizoma Cop-
tidis). Moreover, DM duration was short and the blood
glucose was easy to control, so the amount of the
Huanglian (Rhizoma Coptidis) was relatively less.
Limitations
Several limitations exist, including: (a) the retrospec-
tive nature of the study, (b) the complex pharmacolog-
ic ingredients of the treatments, (c) the use of clinic
medical records to collect information on patients, and
(d) the unequal number of patients at every follow-up
because of the different timings of patient return visits.
DHXD was found to decrease FBG, PBG and HbA1C
in patients with T2DM, reduce body weight, correct
disorders of lipid metabolism, and improve diabetic
symptoms, which may indicate a new optional treat-
ment for DM.
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